JP2008514721A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008514721A5 JP2008514721A5 JP2007534765A JP2007534765A JP2008514721A5 JP 2008514721 A5 JP2008514721 A5 JP 2008514721A5 JP 2007534765 A JP2007534765 A JP 2007534765A JP 2007534765 A JP2007534765 A JP 2007534765A JP 2008514721 A5 JP2008514721 A5 JP 2008514721A5
- Authority
- JP
- Japan
- Prior art keywords
- mtor inhibitor
- inhibitor according
- administered
- therapy
- aml
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940124302 mTOR inhibitor Drugs 0.000 claims 13
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 13
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 2
- 229960000235 temsirolimus Drugs 0.000 claims 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 1
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 229960000684 cytarabine Drugs 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000002702 enteric coating Substances 0.000 claims 1
- 238000009505 enteric coating Methods 0.000 claims 1
- 238000009093 first-line therapy Methods 0.000 claims 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 claims 1
- 229960000908 idarubicin Drugs 0.000 claims 1
- 238000009115 maintenance therapy Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims 1
- 229960003087 tioguanine Drugs 0.000 claims 1
- CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 claims 1
- 229950009819 zotarolimus Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61548504P | 2004-09-30 | 2004-09-30 | |
| PCT/US2005/035047 WO2006039414A2 (en) | 2004-09-30 | 2005-09-30 | Treatment method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008514721A JP2008514721A (ja) | 2008-05-08 |
| JP2008514721A5 true JP2008514721A5 (cg-RX-API-DMAC7.html) | 2008-11-13 |
Family
ID=36143059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007534765A Pending JP2008514721A (ja) | 2004-09-30 | 2005-09-30 | 治療方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080081053A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1809276A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2008514721A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2005292033A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2581372A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2007003790A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006039414A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1478648B1 (en) | 2002-02-01 | 2014-04-30 | ARIAD Pharmaceuticals, Inc. | Phosphorus-containing compounds and uses thereof |
| EP2662082A1 (en) * | 2005-11-14 | 2013-11-13 | Ariad Pharmaceuticals, Incorporated | Administration of mTOR inhibitors |
| EP2004163B1 (en) * | 2006-04-05 | 2014-09-17 | Novartis Pharma AG | Combination of everolimus and vinorelbine |
| US20090311249A1 (en) * | 2006-06-02 | 2009-12-17 | Luca Gianni | Capecitabine Combination Therapy |
| US20100266590A1 (en) * | 2006-08-02 | 2010-10-21 | Demetri George D | Combination therapy |
| US20080161335A1 (en) * | 2006-11-14 | 2008-07-03 | Vladyka Ronald S | Oral formulations |
| TWI597061B (zh) * | 2013-02-20 | 2017-09-01 | 國鼎生物科技股份有限公司 | 治療白血病之方法及組成物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5118677A (en) * | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
| US7041654B2 (en) * | 1997-10-03 | 2006-05-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods and compositions for inducing tumor-specific cytotoxicity |
| EP1478648B1 (en) * | 2002-02-01 | 2014-04-30 | ARIAD Pharmaceuticals, Inc. | Phosphorus-containing compounds and uses thereof |
| US7026330B2 (en) * | 2002-05-30 | 2006-04-11 | The Children's Hospital Of Philadelphia | Methods for treatment of acute lymphocytic leukemia |
| AU2003248813A1 (en) * | 2002-07-05 | 2004-01-23 | Beth Israel Deaconess Medical Center | Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms |
-
2005
- 2005-09-30 CA CA000000004A patent/CA2581372A1/en not_active Abandoned
- 2005-09-30 AU AU2005292033A patent/AU2005292033A1/en not_active Abandoned
- 2005-09-30 EP EP05799834A patent/EP1809276A4/en not_active Withdrawn
- 2005-09-30 MX MX2007003790A patent/MX2007003790A/es unknown
- 2005-09-30 JP JP2007534765A patent/JP2008514721A/ja active Pending
- 2005-09-30 US US11/663,940 patent/US20080081053A1/en not_active Abandoned
- 2005-09-30 WO PCT/US2005/035047 patent/WO2006039414A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009539769A5 (cg-RX-API-DMAC7.html) | ||
| CN102105152B (zh) | 包含cdks抑制剂和抗肿瘤剂的治疗组合 | |
| JP2012526850A5 (cg-RX-API-DMAC7.html) | ||
| JP2012506898A5 (cg-RX-API-DMAC7.html) | ||
| Zorzi et al. | A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium | |
| RU2013102398A (ru) | Лечение рака крови | |
| JP2014524469A5 (cg-RX-API-DMAC7.html) | ||
| WO2009008992A3 (en) | Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mt0rc2 | |
| JP2009515901A5 (cg-RX-API-DMAC7.html) | ||
| RU2009127351A (ru) | Комбинации антифолатного агента в лечении рака | |
| JP2021080296A5 (cg-RX-API-DMAC7.html) | ||
| JP2020523359A5 (cg-RX-API-DMAC7.html) | ||
| Lagler et al. | Treatment of mucosa associated lymphoid tissue lymphoma with a long‐term once‐weekly regimen of oral azithromycin: Results from the phase II MALT—A trial | |
| JP2008514721A5 (cg-RX-API-DMAC7.html) | ||
| JP2017507151A5 (cg-RX-API-DMAC7.html) | ||
| Westermann et al. | A systemic hyperthermia oncologic working group trial: ifosfamide, carboplatin, and etoposide combined with 41.8 C whole-body hyperthermia for metastatic soft tissue sarcoma | |
| JP2010525042A5 (cg-RX-API-DMAC7.html) | ||
| WO2017184086A1 (en) | Method of treating liver cancer | |
| Kobayashi et al. | Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan | |
| CN102834094B (zh) | 有机化合物的组合产品及其制药用途 | |
| Wang et al. | Preclinical investigation of orally bioavailable, potent KRAS Multi inhibitor JAB-23425 | |
| JP2014500259A (ja) | 血液癌を処置する方法 | |
| CN1917885A (zh) | 抗癌疗法 | |
| CN1302777C (zh) | 包括取代的丙烯酰偏端霉素衍生物和放射治疗的抗肿瘤联合疗法 | |
| JP2011513274A (ja) | モルホリニルアントラサイクリン誘導体および脱メチル化剤を含む、抗腫瘍性組合せ |